γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
2019; Elsevier BV; Volume: 134; Issue: 19 Linguagem: Inglês
10.1182/blood.2019000050
ISSN1528-0020
AutoresMargot J. Pont, Tyler J. Hill, Gabriel O. Cole, Joe James Abbott, Jessica L. Kelliher, Alexander I. Salter, Michael Hudecek, Melissa L. Comstock, Anusha Rajan, Bharvin K.R. Patel, Jenna Voutsinas, Qian Wu, Lingfeng Liu, Andrew J. Cowan, Brent L. Wood, Damian J. Green, Stanley R. Riddell,
Tópico(s)Immunotherapy and Immune Responses
ResumoDespite notably high response rates to B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells in multiple myeloma, few patients have a sustained, very good partial or complete response. This article presents a novel strategy to increase the efficacy of BCMA-directed CAR T-cell therapy and shows that γ-secretase inhibitors improve the efficacy of BCMA CAR T cells by increasing BCMA expression and reducing soluble BCMA.
Referência(s)